Are the Effects of Oral and Vaginal Contraceptives on Bone Formation in Young Women Mediated via the Growth Hormone-IGF-I Axis?

Front Endocrinol (Lausanne). 2020 Jun 16:11:334. doi: 10.3389/fendo.2020.00334. eCollection 2020.

Abstract

Purpose: Combined hormonal contraceptive therapy has been associated with negative bone mineral density outcomes that may be route-dependent [i.e., combined oral contraception (COC) vs. contraceptive vaginal ring (CVR)] and involve the hepatic growth hormone (GH)/insulin-like growth factor-I (IGF-I) axis. The objective of the pilot study was to assess the impact of route of contraceptive administration on IGF-I and procollagen type I N-terminal propeptide (PINP) responses to an IGF-I Generation Test. We hypothesized that the peak rise in IGF-I and PINP concentration and area under the curve (AUC) would be attenuated following COC, but not CVR, use. Methods: Healthy, premenopausal women not taking hormonal contraception were recruited. Women were enrolled in the control group (n = 8) or randomly assigned to COC (n = 8) or CVR (n = 8) for two contraceptive cycles. IGF-I Generation Tests were used as a probe to stimulate IGF-I release and were completed during the pre-intervention and intervention phases. Serum IGF-I and PINP were measured during both IGF-I Generation Tests. The study was registered at ClinicalTrials.gov (NCT02367833). Results: Compared to the pre-intervention phase, peak IGF-I concentration in response to the IGF-I Generation Test in the intervention phase was suppressed in the COC group (p < 0.001), but not the CVR or Control groups (p > 0.090). Additionally, compared to the pre-intervention phase, PINP AUC during the intervention phase was suppressed in both COC and CVR groups (p < 0.001), while no difference was observed in the control group (p = 0.980). Conclusion: These data suggest that changes in recombinant human GH-stimulated hepatic IGF-I synthesis in response to combined hormonal contraception (CHC) use are dependent on route of CHC administration, while the influence on PINP is route-independent. Future research is needed to expand these results with larger randomized control trials in all age ranges of women who utilize hormonal contraception. Clinical Trial Registration: www.ClinicalTrials.gov registration NCT02367833.

Keywords: IGF-I generation test; contraceptive vaginal ring; insulin-like growth factor-I; oral contraception; procollagen type I N-terminal propeptide.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravaginal
  • Administration, Oral
  • Adolescent
  • Adult
  • Bone Density / drug effects*
  • Case-Control Studies
  • Contraceptive Agents, Female / administration & dosage*
  • Female
  • Follow-Up Studies
  • Human Growth Hormone / genetics
  • Human Growth Hormone / metabolism*
  • Humans
  • Insulin-Like Growth Factor I / genetics
  • Insulin-Like Growth Factor I / metabolism*
  • Intrauterine Devices / statistics & numerical data*
  • Male
  • Osteogenesis*
  • Peptide Fragments / genetics
  • Peptide Fragments / metabolism*
  • Pilot Projects
  • Procollagen / genetics
  • Procollagen / metabolism*
  • Prospective Studies
  • Young Adult

Substances

  • Contraceptive Agents, Female
  • IGF1 protein, human
  • Peptide Fragments
  • Procollagen
  • procollagen Type I N-terminal peptide
  • Human Growth Hormone
  • Insulin-Like Growth Factor I

Associated data

  • ClinicalTrials.gov/NCT02367833